CN Bio
25 Nov, 2024
Courtesy – CN Bio
The company’s products and services enable developers to recreate complex human tissues and three-dimensional single and multi-organs to increase understanding of disease, human physiology, and drug efficacy.
Its PhysioMimix® suite comprises assay protocols, hardware and consumables to help scientists accurately predict human drug response, and it generates vital safety and efficacy data.
In 2024, CN Bio raised $21 million in the first close of its Series B fundraising round, with $10 million from Bayland Capital and an additional $5.5 million from the founding shareholder, CN Innovations. The company is using the funding to scale up by driving expansion across key global markets and broadening its portfolio of products/services.
Briony Quested